- Home
- TNGX vs NGS Comparison
TNGX vs NGS Comparison
Compare TNGX & NGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- NGS
- Stock Information
- Founded
- TNGX 2014
- NGS 1998
- Country
- TNGX United States
- NGS United States
- Employees
- TNGX N/A
- NGS N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- NGS Oilfield Services/Equipment
- Sector
- TNGX Health Care
- NGS Energy
- Exchange
- TNGX Nasdaq
- NGS Nasdaq
- Market Cap
- TNGX 317.4M
- NGS N/A
- IPO Year
- TNGX N/A
- NGS 2002
- Fundamental
- Price
- TNGX $1.10
- NGS $20.11
- Analyst Decision
- TNGX Strong Buy
- NGS Strong Buy
- Analyst Count
- TNGX 7
- NGS 1
- Target Price
- TNGX $12.33
- NGS $32.00
- AVG Volume (30 Days)
- TNGX 542.7K
- NGS 71.1K
- Earning Date
- TNGX 05-12-2025
- NGS 05-12-2025
- Dividend Yield
- TNGX N/A
- NGS N/A
- EPS Growth
- TNGX N/A
- NGS 260.53
- EPS
- TNGX N/A
- NGS 1.37
- Revenue
- TNGX $42,069,000.00
- NGS $156,742,000.00
- Revenue This Year
- TNGX N/A
- NGS $12.87
- Revenue Next Year
- TNGX N/A
- NGS $15.40
- P/E Ratio
- TNGX N/A
- NGS $14.68
- Revenue Growth
- TNGX 15.17
- NGS 29.36
- 52 Week Low
- TNGX $1.11
- NGS $16.70
- 52 Week High
- TNGX $12.02
- NGS $29.74
- Technical
- Relative Strength Index (RSI)
- TNGX 33.44
- NGS 53.74
- Support Level
- TNGX $1.38
- NGS $17.63
- Resistance Level
- TNGX $1.56
- NGS $19.68
- Average True Range (ATR)
- TNGX 0.16
- NGS 1.00
- MACD
- TNGX -0.01
- NGS 0.28
- Stochastic Oscillator
- TNGX 9.90
- NGS 90.51
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.